Literature DB >> 16570279

Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology.

Peter J F Snijders1, Cornelis J A Hogewoning, Albertus T Hesselink, Johannes Berkhof, Feja J Voorhorst, Maaike C G Bleeker, Chris J L M Meijer.   

Abstract

An increased high-risk human papillomavirus (hrHPV) viral load in cervical scrapings has been proposed as a determinant for high-grade cervical intraepithelial neoplasia (CIN) and cervical cancer (> or =CIN 2), but data so far for HPV types different from HPV 16 are limited and inconsistent. In addition, a viral load threshold to distinguish hrHPV positive women without > or =CIN 2 still has not been defined. Here, we used baseline cervical scrapings of women with normal cytology participating in a large population-based cervical screening trial (i.e. POBASCAM) who were GP5+/6+-PCR positive for 4 common hrHPV types, i.e. HPV 16, 18, 31 or 33, as a reference to arbitrarily define various viral load thresholds (i.e. 25th, 33rd, 50th, 67th and 75th percentiles of the lowest viral load values) for distinguishing women having single infections with these types without high-grade CIN. Viral load assessment was performed by real time type-specific PCR. The viral load threshold values were subsequently validated on abnormal cervical scrapes of 162 women with underlying, histologically confirmed CIN lesions containing 1 of these 4 hrHPV types. All 59 women with CIN 3 had viral load levels that were higher than those of 33% of the women with normal cytology containing the respective hrHPV type detectable by GP5+/6+-PCR (i.e. higher than the 33rd percentile of viral load). By using this 33rd percentile viral load cut-off, sensitivity for CIN 3 of 100% (95% CI 93.9-100) was obtained. Hence, application of this viral load threshold would increase the specificity of HPV testing for HPV 16, 18, 31 and 33-associated prevalent CIN 3 without the cost of a marked reduction in sensitivity. In practice, on the basis of viral load analysis, a less aggressive management can be foreseen for 33% of the women with normal cytology participating in a population-based screening program who are GP5+/6+-PCR positive for HPV 16, 18, 31 or 33. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 16570279     DOI: 10.1002/ijc.21956

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  35 in total

1.  HPV16 viral load and physical state measurement as a potential immediate triage strategy for HR-HPV-infected women: a study in 644 women with single HPV16 infections.

Authors:  Anna Manawapat-Klopfer; Lisa Wang; Juliane Haedicke-Jarboui; Frank Stubenrauch; Christian Munk; Louise T Thomsen; Peter Martus; Susanne K Kjaer; Thomas Iftner
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

2.  Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program.

Authors:  A T Hesselink; N W J Bulkmans; J Berkhof; A T Lorincz; C J L M Meijer; P J F Snijders
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

3.  The 2010 global proficiency study of human papillomavirus genotyping in vaccinology.

Authors:  Carina Eklund; Ola Forslund; Keng-Ling Wallin; Tiequn Zhou; Joakim Dillner
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

4.  Changes in DNA Level of Oncogenic Human Papillomaviruses Other Than Types 16 and 18 in Relation to Risk of Cervical Intraepithelial Neoplasia Grades 2 and 3.

Authors:  Long Fu Xi; Mark Schiffman; James P Hughes; Denise A Galloway; Laura A Koutsky; Nancy B Kiviat
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-05-17       Impact factor: 4.254

5.  Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2-3.

Authors:  Long Fu Xi; Laura A Koutsky; Philip E Castle; Cosette M Wheeler; Denise A Galloway; Constance Mao; Jesse Ho; Nancy B Kiviat
Journal:  J Natl Cancer Inst       Date:  2009-01-27       Impact factor: 13.506

6.  Quantitative human papillomavirus 16 and 18 levels in incident infections and cervical lesion development.

Authors:  Rachel L Winer; Tiffany G Harris; Long Fu Xi; Kathrin U Jansen; James P Hughes; Qinghua Feng; Carolee Welebob; Jesse Ho; Shu-Kuang Lee; Joseph J Carter; Denise A Galloway; Nancy B Kiviat; Laura A Koutsky
Journal:  J Med Virol       Date:  2009-04       Impact factor: 2.327

7.  Human papillomavirus (HPV) types 16, 18, 31, 45 DNA loads and HPV-16 integration in persistent and transient infections in young women.

Authors:  Agnihotram V Ramanakumar; Otelinda Goncalves; Harriet Richardson; Pierre Tellier; Alex Ferenczy; François Coutlée; Eduardo L Franco
Journal:  BMC Infect Dis       Date:  2010-11-11       Impact factor: 3.090

8.  Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women.

Authors:  N Muñoz; G Hernandez-Suarez; F Méndez; M Molano; H Posso; V Moreno; R Murillo; M Ronderos; C Meijer; A Muñoz
Journal:  Br J Cancer       Date:  2009-03-17       Impact factor: 7.640

9.  Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention.

Authors:  Luisa Barzon; Colomba Giorgi; Franco M Buonaguro; Giorgio Palù
Journal:  Infect Agent Cancer       Date:  2008-12-16       Impact factor: 2.965

10.  Patients with usual vulvar intraepithelial neoplasia-related vulvar cancer have an increased risk of cervical abnormalities.

Authors:  R P de Bie; H P van de Nieuwenhof; R L M Bekkers; W J G Melchers; A G Siebers; J Bulten; L F A G Massuger; J A de Hullu
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.